Psilocybin may be as effective as escitalopram in treating depression, study suggests A meta-analysis has found similar effectiveness of psilocybin compared with escitalopram in the treatment of depression, but the study does have limitations.
Copy link to page Download PDF
Psilocybin, the active ingredient in magic mushrooms, could be as effective as escitalopram but the study acknowledges that it would usually be administered alongside psychotherapy Shutterstock.com
Psilocybin could be as effective as escitalopram — a selective serotonin reuptake inhibitor (SSRI) — in treating depressive symptoms, a study has found.
Get unlimited access to all content You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
Already an RPS member or registered? Log in
Become a member of the RPS or subscribe to continue reading and access the full range of information and news on pharmacy.
Become a member or subscribe
Register for free to keep on reading Access two premium articles as a registered user.
Register
Already an RPS member or registered? Log in
Get unlimited access to all content You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
Already an RPS member or registered? Log in
Become a member of the RPS or subscribe to continue reading and access the full range of information and news on pharmacy.
Become a member or subscribe
Register for free to keep on reading Access two premium articles as a registered user.
Register
Already an RPS member or registered? Log in
Get unlimited access to all content You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
Already an RPS member or registered? Log in
Become a member of the RPS or subscribe to continue reading and access the full range of information and news on pharmacy.
Become a member or subscribe
Register for free to keep on reading Access two premium articles as a registered user.
Register
Already an RPS member or registered? Log in
Get unlimited access to all content You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
Already an RPS member or registered? Log in
Become a member of the RPS or subscribe to continue reading and access the full range of information and news on pharmacy.
Become a member or subscribe
Register for free to keep on reading Access two premium articles as a registered user.
Register
Already an RPS member or registered? Log in
Last updated 23 August 2024 15:50